Seasonal variation of anti-PD-1 outcome in melanoma—Results from a Dutch patient cohort
Publikation: Bidrag til tidsskrift › Kommentar/debat › Forskning › fagfællebedømt
Dokumenter
- Fulltext
Forlagets udgivne version, 2,11 MB, PDF-dokument
Originalsprog | Engelsk |
---|---|
Tidsskrift | Pigment Cell and Melanoma Research |
Vol/bind | 37 |
Udgave nummer | 1 |
Antal sider | 7 |
ISSN | 1755-1471 |
DOI |
|
Status | Udgivet - 2024 |
Bibliografisk note
Funding Information:
No funding was obtained for this manuscript. The Dutch Institute for Clinical Auditing (DICA) foundation received a start‐up grant for the Dutch Melanoma Treatment Registry (DMTR) from The Netherlands Organization for Health Research and Development (ZonMW, project number 836002002). The DMTR is structurally funded by Bristol‐Myers Squibb, Merck Sharpe & Dohme, Novartis, and Roche Pharma. Roche Pharma ended their funding in 2019, and Pierre Fabre started funding the DMTR in 2019.
Publisher Copyright:
© 2023 The Authors. Pigment Cell & Melanoma Research published by John Wiley & Sons Ltd.
ID: 372824018